Totals
- Total revenue
- $30,662,355
- Total expenses
- $27,526,933
- Contributions and grants received
- $1,283,375
- Grants paid
- $0
- Program service revenue
- $27,810,618
- Investment income
- $1,529,170
- Other revenue
- $39,192
- Total assets, end of year
- $45,849,022
- Total liabilities, end of year
- $23,048,867
- Net assets or fund balances, end of year
- $22,800,155
- Program services expenses (Part IX)
- $22,538,404
- Management and general expenses
- $4,257,641
- Fundraising expenses
- $730,888
- Program service expenses (Part III)
- $22,538,404
Program services were 81.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$147,666
-
1f · All other contributions, gifts and grants
$1,135,709
-
1g · Noncash contributions included above
$20,182
-
2a · Program service revenue: EYE TISSUE FEES
total $25,393,795 · related or exempt $25,393,795
-
2b · Program service revenue: INTERCOMPANY CHARGES
total $2,257,961 · related or exempt $2,257,961
-
2c · Program service revenue: OTHER REVENUE
total $158,862 · related or exempt $158,862
-
3 · Investment income
total $643,775 · excluded $643,775
-
7a · Gross sales of assets other than inventory
securities $885,397
-
7b · Less cost or other basis and sales expenses
other assets $2
-
7c · Gain or loss
securities $885,397 · other assets -$2
-
7d · Net gain or loss
total $885,395 · excluded $885,395
-
8a · Fundraising events: gross income
$152,143
-
8a · Fundraising events: contributions included on line 1c
$147,666
-
8b · Fundraising events: direct expenses
$112,951
-
8c · Net income from fundraising events
total $39,192 · excluded $39,192
Functional expenses
Part IX, the statement of functional expenses.
-
5 · Compensation of officers, directors and key employees
total $1,339,782 · program services $279,397 · management and general $1,060,385
-
7 · Other salaries and wages
total $9,330,876 · program services $7,353,634 · management and general $1,599,183 · fundraising $378,059
-
8 · Pension plan contributions
total $293,770 · program services $250,923 · management and general $29,642 · fundraising $13,205
-
9 · Other employee benefits
total $1,785,028 · program services $1,426,748 · management and general $284,773 · fundraising $73,507
-
10 · Payroll taxes
total $836,553 · program services $610,920 · management and general $195,137 · fundraising $30,496
-
11b · Fees: legal
total $8,556 · program services $4,711 · management and general $3,845
-
11c · Fees: accounting
total $44,600 · program services $24,556 · management and general $20,044
-
11g · Fees: other
total $429,174 · program services $236,293 · management and general $192,881
-
12 · Advertising and promotion
total $14,584 · management and general $14,584
-
13 · Office expenses
total $226,883 · program services $183,856 · management and general $31,154 · fundraising $11,873
-
14 · Information technology
total $282,629 · program services $231,534 · management and general $41,162 · fundraising $9,933
-
16 · Occupancy
total $1,353,756 · program services $1,101,849 · management and general $202,422 · fundraising $49,485
-
17 · Travel
total $191,395 · program services $141,475 · management and general $46,915 · fundraising $3,005
-
19 · Conferences, conventions and meetings
total $160,223 · program services $52,819 · management and general $93,636 · fundraising $13,768
-
22 · Depreciation, depletion and amortization
total $232,903 · program services $189,562 · management and general $34,827 · fundraising $8,514
-
23 · Insurance
total $374,484 · program services $310,976 · management and general $51,463 · fundraising $12,045
-
24a · Other expenses: CLINICAL LAB & TECH EXP
total $9,753,141 · program services $9,753,141
-
24b · Other expenses: MISCELLANEOUS
total $259,508 · program services $5,468 · management and general $254,971 · fundraising -$931
-
24c · Other expenses: MEMBERSHIP DUES
total $178,018 · program services $178,018
-
24d · Other expenses: BUSINESS DEVELOPMENT
total $167,832 · program services $82,747 · management and general $82,143 · fundraising $2,942
-
24e · All other expenses
total $263,238 · program services $119,777 · management and general $18,474 · fundraising $124,987
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $2,483,366 · end of year $3,479,320
-
2 · Savings and temporary cash investments
beginning of year $5,263,160 · end of year $4,246,975
-
4 · Accounts receivable
beginning of year $2,930,442 · end of year $3,851,794
-
9 · Prepaid expenses and deferred charges
beginning of year $157,170 · end of year $148,372
-
10a · Land, buildings and equipment: cost or other basis
$16,043,671
-
10b · Land, buildings and equipment: accumulated depreciation
$7,433,536
-
10c · Land, buildings and equipment, net
beginning of year $8,105,268 · end of year $8,610,135
-
11 · Investments: publicly traded securities
beginning of year $9,147,484 · end of year $12,720,929
-
14 · Intangible assets
end of year -$1,338,359
-
15 · Other assets
beginning of year $13,441,095 · end of year $14,129,856
-
17 · Accounts payable and accrued expenses
beginning of year $1,901,749 · end of year $2,109,308
-
19 · Deferred revenue
beginning of year $400 · end of year $400
-
24 · Unsecured notes and loans payable
beginning of year $7,059,250 · end of year $6,510,250
-
25 · Other liabilities
beginning of year $13,814,799 · end of year $14,428,909
-
27 · Net assets without donor restrictions
beginning of year $18,606,591 · end of year $22,568,195
-
28 · Net assets with donor restrictions
beginning of year $145,196 · end of year $231,960
Mission and programs · 2023
Mission
EVERSIGHT'S MISSION IS TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. BLINDING EYE DISEASES AFFECT 80 MILLION AMERICANS. THAT MEANS MILLIONS OF PEOPLE CANNOT SEE THEIR LOVED ONES, DRIVE TO WORK OR READ THE NEWSPAPER ON A SUNDAY MORNING. THEIR VISION LOSS RESULTS IN AN ECONOMIC IMPACT OF 51.4 BILLION EVERY YEAR IN THE UNITED STATES ALONE. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL MOTHERS CAN SEE THEIR CHILDREN AND ALL CHILDREN CAN GROW UP TO LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. TO MAKE VISION A REALITY FOR ALL, EVERSIGHT CONTINUOUSLY WORKS TO EXPAND ITS REACH, CONNECT MORE EFFECTIVELY WITH COMMUNITIES IN NEED AND PROVIDE THE GIFT OF SIGHT TO EVERYONE.
Activities or mission (Part I)
EVERSIGHT IS A 501(C)3 NONPROFIT ORGANIZATION WITH THE MISSION TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. THE EVERSIGHT NETWORK IS RESPONSIBLE FOR RECOVERING, EVALUATING AND PROVIDING HUMAN EYE TISSUE FOR TRANSPLANTATION; ADVANCING RESEARCH INTO THE CAUSES AND CURES OF BLINDING EYE CONDITIONS; PROMOTING DONATION AWARENESS THROUGH PUBLIC AND PROFESSIONAL EDUCATION; AND PROVIDING HUMANITARIAN AID TO PEOPLE AROUND THE WORLD IN NEED OF CORNEAL TRANSPLANTATION. FOUNDED IN 1947, EVERSIGHT MAINTAINS ITS COMMITMENT TO EXCELLENCE AS AN ACCREDITED MEMBER OF THE EYE BANK ASSOCIATION OF AMERICA (EBAA) AND BY MEETING THE HIGHEST QUALITY STANDARDS SET BY THE U.S. FOOD AND DRUG ADMINISTRATION. THE NONPROFIT OPERATES 24/7/365 IN CONNECTICUT, ILLINOIS, MICHIGAN, NEW JERSEY, OHIO AND SOUTH KOREA, AND COLLABORATES WITH SURGEONS, RESEARCHERS, ACADEMIC MEDICAL CENTERS AND EYE BANKS ACROSS THE UNITED STATES AND ABROAD. EVERSIGHT WORKS WITH THE
-
RESORING SIGHT EVERSIGHT CONTINUES TO TAKE MEANINGFUL STEPS TOWARD TRANSFORMING THE FUTURE OF VISION CARE BY SUPPORTING SUSTAINABLE EYE BANKING INFRASTRUCTURE AND PROVIDING PRICELESS CLINICAL EDUCATION. IN 2023, EVERSIGHT PROVIDED THE GIFT OF SIGHT TO MORE THAN 9,200 PEOPLE ACROSS THE UNITED STATES AND AROUND THE WORLD. EVERSIGHT PROVIDED 42 CORNEAS FOR SIGHT-RESTORING TRANSPLANTS GRATIS OR AT A REDUCED FEE FOR UNINSURED PATIENTS. EVERSIGHT'S WORK BEGAN IN 1947 WITH THE ESTABLISHMENT OF THE FOURTH EYE BANK IN THE UNITED STATES, THEN KNOWN AS THE ILLINOIS EYE-BANK. OVER TIME, NONPROFIT EYE BANKS WERE ESTABLISHED IN EVERY STATE TO MEET THE CRITICAL DEMAND FOR CORNEAL TISSUE TO TREAT PREVENTABLE BLINDNESS. IN 1985, THE ILLINOIS EYE-BANK AND MICHIGAN EYE-BANK FORMED A PARTNERSHIP ONE THAT WOULD EARN A REPUTATION FOR CLINICAL EXCELLENCE MADE POSSIBLE BY SOME OF THE FINEST MEDICAL DIRECTORS, STAFF AND BOARD MEMBERS IN THE EYE BANKING FIELD. THE SUCCESS OF THE ORGANIZATION ATTRACTED AFFILIATIONS WITH OTHER REGIONAL EYE BANKS FORMING ONE OF THE LARGEST NETWORKS OF EYE BANKS IN THE U.S. IN 2015, THE NETWORK BECAME KNOWN AS EVERSIGHT, ALL WORKING TOGETHER AS A UNIFIED OPERATION TO DELIVER THE HIGHEST QUALITY SERVICES TO SURGEONS AND THEIR PATIENTS AND TO CONTINUE TO GROW OUR IMPACT AROUND THE WORLD. EVERSIGHT PROVIDED MORE THAN 13,800 TISSUES FOR TRANSPLANTATION, RESEARCH AND EDUCATION GLOBALLY IN 2023. WE WORKED OR PLACED TISSUE WITH PHYSICIANS AND RESEARCHERS IN 33 COUNTRIES AND FACILITATED TRAINING FOR 865 CLINICIANS. TOGETHER WITH ALL OUR PARTNERS-ADVOCATES, DONOR FAMILIES, TRANSPLANT RECIPIENTS, SURGEONS, LIONS, FELLOW EYE BANKS, HEALTHCARE LEADERS, PHILANTHROPIC SUPPORTERS AND MANY OTHERS-WE WERE ABLE TO MAKE VISION A REALITY FOR MORE PEOPLE WORLDWIDE.
Expenses $21,274,312 · Revenue $27,810,618
-
FINDING A CURE IN THE PURSUIT OF ELIMINATING BLINDING EYE DISEASES, EVERSIGHT ESTABLISHED THE EVERSIGHT CENTER FOR VISION AND EYE BANKING RESEARCH IN CLEVELAND, OHIO, TO PROVIDE LEADING OPHTHALMOLOGY RESEARCHERS WITH THE RESOURCES THEY NEED TO FIND CURES AND TREATMENTS FOR EYE DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND GLAUCOMA. EVERSIGHT PROVIDED MORE THAN 4,500 TISSUES FOR RESEARCH AND EDUCATION PURPOSES IN 2023. OUR IN-HOUSE RESEARCH TEAM ALSO PROVIDED EVERSIGHT PARTNERS WITH VALUABLE RESEARCH AND DEVELOPMENT SERVICES, AND PIONEERED NEW EYE BANKING PRACTICES. SINCE 2014, THE EVERSIGHT RESEARCHERS HAVE AUTHORED 47 PUBLICATIONS AND GIVEN 15+ PRESENTATIONS AT INTERNATIONAL CONFERENCES, AND SUPPORTED 230+ PUBLICATIONS OF OUR COLLABORATORS. THE TEAM PUBLISHED EIGHT PEER-REVIEWED PAPERS IN 2023, COVERING TOPICS INCLUDING: BIOLOGIC THERAPEUTICS AND REGENERATIVE MEDICINE; CORNEAL EPITHELIAL HEALING AND STEM CELLS; WET LAB METHODS FOR DMEK SURGICAL TRAINING; RETINAL HISTOLOGY IN RARE GENETIC DISEASE; LITERATURE REVIEW OF CHILDHOOD VISION LOSS; IMPACT OF COVID-19 ON EYE BANKING; DSAEK CELL LOSS IN PRELOADED DEVICES; AND MORE. WITH OUR MANY ACADEMIC PARTNERS, EVERSIGHT RESEARCHERS HAVE CONTRIBUTED TO A TOTAL OF 316 PEER-REVIEWED SCIENTIFIC PAPERS THAT HAVE GARNERED 6,000 CITATIONS AND COUNTING. EVERSIGHT HAS A LONGSTANDING TRACK RECORD OF RESEARCH AND DEVELOPMENT, HAVING AWARDING MORE THAN 4 MILLION IN GRANTS TO DATE THAT STIMULATE PIONEERING CLINICAL AND BASIC SCIENCE RESEARCH AIMING TO DEVELOP NEW WAYS TO RESTORE SIGHT, PREVENT BLINDNESS AND ULTIMATELY HELP PATIENTS LIVE LIFE TO THE FULLEST. SINCE 1980, OUR EYE & VISION RESEARCH GRANT PROGRAM HAS SUPPORTED RESEARCHERS AT LEADING ACADEMIC MEDICAL INSTITUTIONS INCLUDING HARVARD, TUFTS, CLEVELAND CLINIC, CASE WESTERN RESERVE, UNIVERSITY OF MICHIGAN, NORTHWESTERN AND MORE. BY DESIGN, EVERSIGHT'S GRANT PROGRAM PROVIDES CRITICAL, EARLY-STAGE FUNDING THAT IS INTENDED TO DRIVE FOUNDATIONAL RESEARCH AND DISCOVERY. MANY OF THESE PROJECTS HAVE STIMULATED LARGER-SCALE STUDIES AND WON FURTHER FINANCIAL SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH. IN THE 2024 FUNDING CYCLE, EVERSIGHT AWARDED FOUR GRANTS AT TUFTS UNIVERSITY, WAYNE STATE UNIVERSITY AND UNIVERSITY OF MICHIGAN TO ADVANCE STUDIES TO INVESTIGATE THE EFFICIENCY OF LOCAL ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS (PDCS) IN IMPROVING CORNEA GRAFT SURVIVAL IN HIGH-RISK TRANSPLANTATION; DUAL-ACTING NANOFORMULATIONS FOR THE TREATMENT OF OCULAR BACTERIAL INFECTIONS; PATHOETIOLOGY OF EXTRACELLULAR RETINAL DEPOSITS THAT CAUSE IRREVERSIBLE BLINDNESS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) BY DEFINING THE MECHANISM AND COMPOSITION OF RETINAL PIGMENT EPITHELIAL (RPE) LIPOPROTEIN SECRETION; AND OPTIMAL VECTORS AND METHODS FOR DELIVERING GENE BASE EDITING REAGENTS TO TREAT CORNEAL DYSTROPHIES CAUSED BY TGFBI GENE MUTATIONS. EACH YEAR, RECIPIENTS ARE SELECTED BY AN INDEPENDENT REVIEW PANEL OF ACADEMIC RESEARCHERS AND OPHTHALMOLOGISTS. THIS DISTINGUISHED PANEL AWARDS PROPOSALS THAT ENCOURAGE MEANINGFUL SCIENTIFIC INQUISITION AND ALIGN WITH EVERSIGHT'S MISSION TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH.
Expenses $141,201
-
SUSTAINABLE INTERNATIONAL IMPACT EVERSIGHT WORKS TO ELIMINATE CORNEAL BLINDNESS WORLDWIDE THROUGH EYE BANK DEVELOPMENT, CLINICAL TRAINING AND TISSUE PROVISION. WITH MORE THAN 75 YEARS OF EYE BANKING EXPERTISE, WE DELIVER BOTH SHORT- AND LONG-TERM SOLUTIONS TO TRANSFORM THE LIVES OF MORE THAN 12 MILLION PEOPLE SUFFERING FROM CORNEAL BLINDNESS GLOBALLY. IN 2023, EVERSIGHT INTERNATIONAL PROVIDED MORE THAN 3,800 TISSUES FOR TRANSPLANT AND WORKED WITH SURGEONS IN 32 COUNTRIES OUTSIDE THE UNITED STATES, MAKING THE GIFT OF SIGHT POSSIBLE FOR MANY IN NEED. EVERSIGHT PROVIDED 99 CORNEA TISSUES FOR SIGHT-RESTORING TRANSPLANTS GRATIS OR AT A REDUCED RATE FOR MEDICAL MISSIONS AND UNINSURED PATIENTS OUTSIDE THE UNITED STATES. IN MEDICALLY UNDERSERVED AREAS, EVERSIGHT GLOBAL DEVELOPMENT FOSTERS AUTHENTIC RELATIONSHIPS WITH LOCAL LEADERS TO ESTABLISH CULTURALLY INFORMED EYE DONATION FRAMEWORKS AND SUSTAINABLE EYE BANKING INFRASTRUCTURE. OUR EXPERIENCED TEAM OFFERS VITAL CLINICAL TRAINING AND EDUCATION TO EYE SURGEONS AND EYE BANK TECHNICIANS ON THE LATEST CLINICAL METHODS, IMPROVING ACCESS TO LIFE-CHANGING TRANSPLANTS. THROUGH THE INCREDIBLE GENEROSITY OF OUR DONORS AND DONOR FAMILIES, EVERSIGHT GLOBAL DEVELOPMENT ALSO PROVIDES CORNEAL TISSUE FROM THE UNITED STATES FOR TRANSPLANT AND RESEARCH GLOBALLY, PROVIDING HOPE FOR THE FUTURE AND RESTORING SIGHT TO PATIENTS IN NEED. OUR GLOBAL MISSION IS INFORMED BY AND ALIGNS WITH THE UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS (SDGS), WITH PARTICULAR ATTENTION GIVEN TO: 3 GOOD HEALTH AND WELL-BEING, 4 QUALITY EDUCATION, 8 DECENT WORK AND ECONOMIC GROWTH, 10 REDUCED INEQUALITIES AND 11 SUSTAINABLE CITIES & COMMUNITIES. ACCORDING TO THE WORLD HEALTH ORGANIZATION, EVERY DOLLAR SPENT ON IMPROVING EYE HEALTH IN UNDERDEVELOPED AREAS GENERATES A FOUR-FOLD RETURN ON INVESTMENT. TO ADDRESS SYSTEMIC UNMET NEED, EVERSIGHT ACTIVELY WORKS WITH MEDICAL PROFESSIONALS, GOVERNMENTS, VISION HEALTH ORGANIZATIONS AND OTHER NGOS IN REGIONS LACKING EYE BANKS AND INFRASTRUCTURE, INCLUDING UNITED ARAB EMIRATES, PAKISTAN AND SOUTH KOREA. WITH PROVEN EYE BANKING AND TECHNICAL TRAINING PRACTICES-AND HAVING PLAYED A PART IN THE ELIMINATION OF THE U.S. CORNEA TRANSPLANT WAITING LIST-EVERSIGHT IS UNIQUELY QUALIFIED TO WORK WITH COUNTRIES LACKING TRANSPLANT PROGRAMS TO HELP THEM ESTABLISH NATIONAL NETWORKS FOR EYE BANKING AND CORNEA DONATION WITH CULTURALLY APPROPRIATE DONATION MODELS AND STATE-OF-THE-ART CLINICAL CAPABILITIES. GLOBALLY, AN ESTIMATED 2.2 BILLION PEOPLE ARE IMPACTED BY BLINDNESS AND VISUAL IMPAIRMENT. NINETY PERCENT OF VISION-IMPAIRED PEOPLE LIVE IN LOW- AND MIDDLE- INCOME COUNTRIES. APPROXIMATELY ONE BILLION OF THESE INDIVIDUALS ARE COPING WITH BLINDNESS OR VISUAL IMPAIRMENT THAT CAN BE CHARACTERIZED AS PREVENTABLE OR NOT SUFFICIENTLY ADDRESSED. VISION LOSS RESULTS IN SUBSTANTIAL ECONOMIC IMPACT WORLDWIDE DUE TO THE INABILITY OF PEOPLE WHO ARE VISION IMPAIRED TO CONTRIBUTE TO THEIR FULLEST IN THEIR COMMUNITIES. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL PEOPLE IN EVERY COMMUNITY CAN LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. WHILE PROVIDING FOR IMMEDIATE GLOBAL CORNEA TRANSPLANT NEEDS WITH U.S. DONOR TISSUE, EVERSIGHT CONTINUES TO ADDRESS THE GLOBAL BURDEN BY EMPOWERING INTERNATIONAL COMMUNITIES TO TAKE MEANINGFUL, SUSTAINABLE STEPS EVERY DAY TO MAKE VISION A REALITY FOR ALL.
Expenses $1,122,891
As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
MICHAEL O'KEEFE
COO
- Total calculated
- $279,397
- From this org
- $219,990
- From related orgs
- $0
- Other
- $59,407
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $219,990
- Bonus
- not reported
- Other
- not reported
- Deferred
- $13,603
- Nontaxable benefits
- $45,804
- Filer's total
- $279,397
-
JULIE COLLINS
CFO
- Total calculated
- $284,286
- From this org
- $224,333
- From related orgs
- $0
- Other
- $59,953
- Hours/week
- 50 + 7.5 related
Schedule J breakdown matched by us
- Base
- $224,333
- Bonus
- not reported
- Other
- not reported
- Deferred
- $14,148
- Nontaxable benefits
- $45,805
- Filer's total
- $284,286
-
MICHAEL TITUS
VP CLINICAL
- Total calculated
- $238,244
- From this org
- $178,075
- From related orgs
- $0
- Other
- $60,169
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $178,075
- Bonus
- not reported
- Other
- not reported
- Deferred
- $12,541
- Nontaxable benefits
- $47,628
- Filer's total
- $238,244
-
DIANE HOLLINGSWORTH
PRESIDENT &
- Total calculated
- $332,677
- From this org
- $264,097
- From related orgs
- $0
- Other
- $68,580
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $264,097
- Bonus
- not reported
- Other
- not reported
- Deferred
- $17,139
- Nontaxable benefits
- $51,441
- Filer's total
- $332,677
-
BRET HOPMAN
VP MARKETING
- Total calculated
- $205,178
- From this org
- $153,446
- From related orgs
- $0
- Other
- $51,732
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $153,446
- Bonus
- not reported
- Other
- not reported
- Deferred
- $11,023
- Nontaxable benefits
- $40,709
- Filer's total
- $205,178
-
PATTY JO HERNDON
CHAIR
- Total calculated
- $0
- Hours/week
- 1
-
KATHY L ZELENOCK
VICE CHAIR
- Total calculated
- $0
- Hours/week
- 1
-
DANIELLE E D'ARCY
TREASURER
- Total calculated
- $0
- Hours/week
- 1
-
MAHMOUD N GHAZZI MD PHD
SECRETARY
- Total calculated
- $0
- Hours/week
- 1
-
JAROLD ANDERSON
IMM. PAST CH
- Total calculated
- $0
- Hours/week
- 1
-
LORENZO CERVANTES MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
JONATHAN LASS MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
SHAHZAD MIAN MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
CAROL CUNNINGHAM MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
SANDRA FLETCHER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
PROBI KAPUR
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
JOSEPH RADTKA
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
CAROLYN M WELSH
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
PETER WROBLEWSKI
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
CATHERINE MCCLORY
DIR. COMPLIA
- Total calculated
- $177,705
- From this org
- $146,074
- From related orgs
- $0
- Other
- $31,631
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $146,074
- Bonus
- not reported
- Other
- not reported
- Deferred
- $9,541
- Nontaxable benefits
- $22,090
- Filer's total
- $177,705
-
INDU VADAKKEPATTATH
DATA SCI. &
- Total calculated
- $174,458
- From this org
- $142,932
- From related orgs
- $0
- Other
- $31,526
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $142,932
- Bonus
- not reported
- Other
- not reported
- Deferred
- $9,413
- Nontaxable benefits
- $22,113
- Filer's total
- $174,458
-
ONKAR SAWANT
DIR. RESEARC
- Total calculated
- $190,138
- From this org
- $158,673
- From related orgs
- $0
- Other
- $31,465
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $158,673
- Bonus
- not reported
- Other
- not reported
- Deferred
- $10,214
- Nontaxable benefits
- $21,251
- Filer's total
- $190,138
-
KARA KELLY
DIR. PARTN.
- Total calculated
- $129,624
- From this org
- $106,022
- From related orgs
- $0
- Other
- $23,602
- Hours/week
- 50
-
CAITLIN LOPES
DIR. PARTN.
- Total calculated
- $157,556
- From this org
- $111,233
- From related orgs
- $0
- Other
- $46,323
- Hours/week
- 50
Schedule J breakdown matched by us
- Base
- $111,233
- Bonus
- not reported
- Other
- not reported
- Deferred
- $7,902
- Nontaxable benefits
- $38,421
- Filer's total
- $157,556
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
No itemized grants to organizations on this return.
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
3 · EYE BANK · MI · controlled entity
Directly controlled by EVERSIGHT EVERSIGHT
-
3 · EYE BANK · NJ · controlled entity
Directly controlled by EVERSIGHT EVERSIGHT
-
3 · EYE BANK · MI · controlled entity
Directly controlled by EVERSIGHT EVERSIGHT
-
3 · EYE BANK · IL · controlled entity
Directly controlled by EVERSIGHT EVERSIGHT
-
3 · SOFTWARE · MI · controlled entity
Directly controlled by EVERSIGHT EVERSIGHT
-
3 · EYE BANK · OH · controlled entity
Directly controlled by EVERSIGHT EVERSIGHT
-
3 · EYE BANK · CT · controlled entity
Directly controlled by EVERSIGHT EVERSIGHT
Taxable family on this return
Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.
Related corporations and trusts
Part IV: related organizations taxable as a corporation or trust.
-
EVERSIGHT KOREA LLC
C CORP · EYE BANK · KS
Directly controlled by EVER INT EVERSIGHT INTERNATIONAL
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 7 August 2024
- IRS schema version
- 2023v5.0
- Source object
- 202412229349300706
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.